Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study

Articolo

Data di Pubblicazione:

2022

Citazione:

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study / G. Senna, M. Aliani, E. Altieri, P. Bracciale, L. Brussino, M.F. Caiaffa, P. Cameli, G.W. Canonica, C. Caruso, M. D'Amato, F. De Michele, S. Del Giacco, F. Di Marco, F. Menzella, G. Pelaia, P. Rogliani, M. Romagnoli, P. Schino, J.W. Schroeder, A. Vultaggio, S. Rizzoli, A. Zullo, S. Boarino, M. Palmisano, A. Rossi, G. Vitiello, S. Centanni. - In: JOURNAL OF ASTHMA AND ALLERGY. - ISSN 1178-6965. - 15:(2022), pp. 1593-1604. [10.2147/JAA.S383012]

Abstract:

Benralizumab effectively reduces severe eosinophilic asthma (SEA) exacerbations in patients with a wide range of baseline blood eosinophil count (BEC). Patients included in real-world studies are often characterized by high mean/median BEC, while patients with BEC close to 300 cells/mm3 are poorly represented. This post hoc analysis from the Italian study ANANKE aims to define the clinical features and corroborate the efficacy of benralizumab in real world in the BEC 300-450 cells/mm3 subset of patients.

Tipologia IRIS:

01 - Articolo su periodico

Keywords:

benralizumab; blood eosinophil count; observational; real-life; real-world evidence; severe eosinophilic asthma

Elenco autori: